US OptionsDetailed Quotes
SYK240920C400000
- 0.28
- -0.08-22.22%
15min DelayClose Aug 23 16:00 ET
0.42High0.28Low
0.42Open0.36Pre Close2 Volume114 Open Interest400.00Strike Price70.00Turnover23.32%IV13.30%PremiumSep 20, 2024Expiry Date0.00Intrinsic Value100Multiplier27DDays to Expiry0.28Extrinsic Value100Contract SizeAmericanOptions Type0.0323Delta0.0032Gamma1261.75Leverage Ratio-0.0305Theta0.0084Rho40.81Eff Leverage0.0703Vega
Stryker Corp Stock Discussion
Sign in to post a comment
The stock price of $Intuitive Surgical (ISRG.US)$ , the maker of Da Vinci surgical robot system surged 9.34% after its earnings report on Friday, and its market value exceeded $160 billion.
Second quarter revenue of $2.01 billion increased by 14% compared with $1.76 billion in the second quarter of 2023. The second quarter GAAP net income attributable to Intuitive was $52...
Second quarter revenue of $2.01 billion increased by 14% compared with $1.76 billion in the second quarter of 2023. The second quarter GAAP net income attributable to Intuitive was $52...
+1
24
1
The recent insider sale of Stryker shares at the current price is viewed negatively. However, high insider ownership is seen positively, suggesting management's consideration for shareholders. Yet, the absence of insider buying over the past year is worrisome.
The EPS decline doesn't align with share price changes, indicating other factors. Management might be prioritizing revenue growth over EPS. The company's recent performance improvement suggests potential business momentum.
$Stryker Corp (SYK.US)$ shares advanced 6.6% after the company gave a better-than-expected outlook for 2024 and delivered an earnings beat, prompting analysts to upgrade the stock.
The company sees 2024 adjusted earnings to reach $11.70 to $12 a share, according to its press release. That's higher than the $11.54 estimate of analysts polled by Capital IQ, according to MT Newswires.
"Based on our momentum for 2023, strong proce...
The company sees 2024 adjusted earnings to reach $11.70 to $12 a share, according to its press release. That's higher than the $11.54 estimate of analysts polled by Capital IQ, according to MT Newswires.
"Based on our momentum for 2023, strong proce...
3
Investors feel Stryker's high P/E ratio is justified due to its favorable earnings outlook. Their optimism on consistent earnings growth maintains the elevated ratio as expectations for a drop in earnings are low. A significant change in conditions could alter this supportive investor sentiment.
Following a turbulent period, there has been a notable change in the trajectory of biotech stocks. After experiencing significant downturns in 2021 and 2022, the $SPDR S&P Biotech ETF (XBI.US)$ has seen an increase of 5.5% in the current year. However, it continues to trail considerably behind the $S&P 500 Index (.SPX.US)$, which has achieved a 24% gain. However, analysts indicate that the previously cool sent...
29
1
Baird advocates medtech companies such as Alcon, Stryker, and Cooper due to product and pricing strengths. Belief is strong in Alcon's 2024 margin possibilities, Stryker's premium pricing and predicted robust orthopedic demand, and projected revenue growth for Boston Scientific and Axonics.
No comment yet
105535782 : ok